Guide · Updated November 2026

GLP-1 and Thyroid Cancer Risk: What the Data Shows

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry an FDA boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The warning is based on rodent studies at clinically relevant exposures. The FDA labels say it is unknown whether these drugs cause MTC in humans. Large observational studies disagree: a French study found a higher risk, and a Scandinavian study did not. MTC makes up less than 5% of thyroid cancers. People with a personal or family history of MTC, or with MEN 2, should not take these medications.

Almost every GLP-1 medication on the market carries the same boxed warning about thyroid C-cell tumors, including medullary thyroid cancer. It is the most prominent warning on the label, printed in bold before anything else. If you have read the prescribing information for semaglutide or tirzepatide, you have seen it. And if you are considering starting a GLP-1 for weight loss, the GLP-1 thyroid cancer risk question has probably crossed your mind.

I remember reading through the Mounjaro prescribing info before my first injection and pausing at that warning. A boxed warning about cancer is hard to ignore. But the story behind it is more nuanced than the label suggests. The warning exists because of what happened in rodents. The human evidence is still being built, and so far it is mixed.

Here is what the data actually shows.

Where the GLP-1 Thyroid Cancer Concern Comes From

The concern traces back to animal studies. According to the Wegovy prescribing information, semaglutide caused a dose-dependent and duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) in mice and rats after lifetime exposure at clinically relevant plasma exposures. The Zepbound prescribing information reports the same pattern for tirzepatide in rats.

In other words, these were not only absurdly high doses. The exposures were in the range people get from treatment. That is why the FDA requires the boxed warning.

Both labels say the same thing about people: it is unknown whether the drug causes thyroid C-cell tumors, including MTC, in humans, because the human relevance of the rodent tumors has not been determined. The Wegovy label adds that MTC cases have been reported in people taking liraglutide, another GLP-1 drug, after it came to market, but those reports cannot establish or rule out a causal link.

Why Rats May Not Be Humans (In This Case)

Researchers have proposed that rodent thyroid C-cells respond to GLP-1 stimulation much more than human C-cells do. That is the main reason many endocrinologists think the rodent signal may not translate to people. But the labels are explicit that human relevance has not been determined, so this is a hypothesis, not a settled answer.

What Clinical Trials Can and Cannot Tell Us

The major weight loss trials tracked safety for a year or more. They are useful, but MTC is rare, and these trials were not big or long enough to rule out a small increase in a rare cancer.

Trial	Drug	Patients	Length	Main result
STEP 1	Semaglutide 2.4 mg	1,961	68 weeks	-14.9% mean weight change
SURMOUNT-1	Tirzepatide 5/10/15 mg	2,539	72 weeks	-15.0% to -20.9% mean weight change
SELECT	Semaglutide 2.4 mg	17,604	Mean follow-up 39.8 months	20% lower risk of major cardiovascular events

SELECT is the largest and longest of these. It enrolled 17,604 adults with heart disease and overweight or obesity, without diabetes. It was designed to test heart outcomes, not cancer.

What Real-World Data Shows

Clinical trials are controlled environments with selected patients. Observational studies cover broader populations over longer periods, but they carry their own biases.

The French National Health Insurance Study (2023)

A French nested case-control study published in Diabetes Care in 2023 used the national health insurance database for people with type 2 diabetes. It compared 2,562 people with thyroid cancer to 45,184 matched controls. Using GLP-1 drugs for 1 to 3 years was linked to a higher risk of all thyroid cancer (adjusted hazard ratio 1.58) and of medullary thyroid cancer specifically (adjusted hazard ratio 1.78).

This study generated headlines, and it should be taken seriously. One possible explanation that researchers raise is detection bias: people on GLP-1 medications may see doctors more often and get more neck exams or imaging, which can find small cancers that would otherwise go unnoticed. An observational study cannot prove cause and effect either way.

The Scandinavian Cohort Study (2024)

A large cohort study in The BMJ compared people starting GLP-1 drugs with people starting DPP-4 inhibitors across Denmark, Norway, and Sweden from 2007 to 2021. Thyroid cancer occurred in 76 of 145,410 GLP-1 users (1.33 per 10,000 person-years) and 184 of 291,667 DPP-4 users (1.46 per 10,000 person-years). The hazard ratio was 0.93, meaning no increase was found. For MTC, the hazard ratio was 1.19, but with very few cases the confidence interval was wide (0.37 to 3.86). Mean follow-up was 3.9 years.

“Our study covers a broad group of patients and provides strong support that GLP-1 analogues are not associated with an increased risk of thyroid cancer,” said Björn Pasternak, MD, PhD, principal researcher at the Department of Medicine, Solna, at Karolinska Institutet, who led the study, in the institute’s announcement of the findings.

The Key Distinction: MTC vs. All Thyroid Cancer

The boxed warning is specifically about medullary thyroid carcinoma. The American Cancer Society says MTC accounts for less than 5% of thyroid cancers, while about 8 out of 10 are papillary cancers.

That matters for reading the studies. An increase in “all thyroid cancer” is mostly an increase in papillary cancer. The French study did report a higher MTC risk. The Scandinavian study did not find one, but it had too few MTC cases to rule one out. The honest summary is that the MTC question is not settled.

Compare GLP-1 providers

Browse Provider Directory →

GLP-1 Thyroid Cancer Risk in Context

To put the risk in perspective, it helps to compare it with the more common side effects and the measured benefits.

Item	What the source reports
Thyroid cancer in Scandinavian GLP-1 users	1.33 per 10,000 person-years
Nausea on Wegovy 2.4 mg (weight-loss trials)	44% vs 16% on placebo
Nausea on Zepbound 15 mg (weight-loss trials)	28% vs 8% on placebo
Gallstones on Wegovy injection	1.6% vs 0.7% on placebo
Cardiovascular benefit (SELECT)	20% lower risk of major cardiovascular events

The nausea and gallstone figures come from the Wegovy and Zepbound prescribing information. The side effects you are most likely to experience on a GLP-1 are gastrointestinal. The thyroid cancer question is about a rare cancer with mixed human evidence.

That does not mean it should be dismissed. It means it should be weighed accurately against real, measurable benefits like weight loss and fewer cardiovascular events.

Who Should Not Take GLP-1 Medications

The FDA boxed warning is not just theoretical caution. For certain people, it is a hard stop.

The labels say these drugs are contraindicated if you have:

A personal history of medullary thyroid carcinoma
A family history of MTC
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

MEN 2 is an inherited condition that carries a high risk of MTC. The ACS notes that about 1 in 4 MTC cases are familial.

What about calcitonin testing? Calcitonin is a hormone made by thyroid C-cells, and high levels can point to MTC. But the Wegovy label says routine calcitonin or thyroid ultrasound monitoring is of uncertain value for catching MTC early, and it may lead to unnecessary procedures. It also says that patients with thyroid nodules, or with a significantly elevated calcitonin, should be further evaluated.

If you are concerned about your thyroid while on a GLP-1, talk to your prescriber. Individual risk factors may warrant closer follow-up.

What About the Newer GLP-1 Medications in Development

The next generation of weight loss drugs includes retatrutide (a triple agonist from Eli Lilly), CagriSema (Novo Nordisk’s semaglutide plus cagrilintide combination), and amycretin (a GLP-1 and amylin agonist from Novo Nordisk).

All of these drugs act on the GLP-1 receptor. If approved, they will very likely carry a similar thyroid warning.

The oral formulations carry it too. Oral Wegovy shares the boxed warning in the combined Wegovy label. So does orforglipron (Foundayo), which the FDA approved on April 1, 2026. The Foundayo label notes that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but it still carries the warning because it is active at the human GLP-1 receptor.

Nothing about the route of administration changes the underlying pharmacology. If the drug activates the GLP-1 receptor, the thyroid C-cell warning applies.

My Take

I have been on Mounjaro for months. I track my body composition with DEXA scans. I pay attention to the side effects, the research, and the data. The thyroid cancer warning was one of the first things I looked into before starting.

After reviewing the available evidence, I view the thyroid risk as low for people without a personal or family history of MTC or MEN 2. The rodent data is real and was seen at clinically relevant exposures. The human data is mixed: one large study found a higher risk and another did not. Detection bias may explain part of the French finding, but that has not been proven.

That said, I am not a doctor. If you have any family history of thyroid cancer, bring it up with your prescriber before starting treatment. And if you develop a new lump in your neck, trouble swallowing, shortness of breath, or persistent hoarseness while on a GLP-1, get it checked promptly. Those are the symptoms the labels list.

The cost of these medications is already a barrier for many people. Fear that is not based on the data makes it harder for people who could benefit from treatment. Based on what I reviewed in November 2026, thyroid cancer is a rare risk that deserves an honest conversation, not panic.

FAQ

Does Ozempic cause thyroid cancer?

It is not known. The FDA labels say it is unknown whether semaglutide causes thyroid C-cell tumors, including MTC, in humans. The boxed warning is based on rodent studies where semaglutide caused C-cell tumors at clinically relevant exposures. Human observational studies are mixed: a French study found a higher risk, and a Scandinavian study did not.

Should I get my thyroid checked before starting a GLP-1?

Tell your prescriber about any personal or family history of thyroid cancer or MEN 2, since those are reasons not to take these drugs. The Wegovy label says routine calcitonin or thyroid ultrasound monitoring is of uncertain value and may lead to unnecessary procedures. Any thyroid nodule found on exam or imaging should be evaluated.

What are the symptoms of medullary thyroid carcinoma?

The labels list a mass in the neck, trouble swallowing, shortness of breath, and persistent hoarseness as symptoms to report. If you notice any of these while on a GLP-1, contact your doctor for evaluation.

Is tirzepatide (Mounjaro/Zepbound) safer than semaglutide for thyroid risk?

There is no evidence that one is safer than the other for thyroid risk. Both carry the same type of boxed warning because both caused thyroid C-cell tumors in rodents. The choice between them should be based on other factors like weight loss efficacy, side effect profile, and cost.

How long does the thyroid cancer risk last after stopping a GLP-1?

This question does not have a definitive answer because a thyroid cancer risk has not been established or ruled out in humans. The rodent tumors appeared after lifetime exposure. Talk to your prescriber about follow-up, and see our guide to maintenance and exit strategies after GLP-1 therapy.

What we checked

This AI-assisted public-source desk check reviewed the current Wegovy, Zepbound, and Foundayo prescribing information, the STEP 1, SURMOUNT-1, and SELECT abstracts on PubMed, the French and Scandinavian thyroid cancer studies, and the American Cancer Society thyroid cancer page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Related

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides